Becton, Dickinson and Company (BDX) research, news, and more from GeoInvesting

Company description

Mon, 09 Mar 2020 20:13:47 GMT

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Comments & Business Outlook

Fri, 31 Jul 2009 04:00:00 GMT

"We are pleased with our solid third quarter performance and, in particular, the results achieved by our Diagnostics segment and our Medical segment's Pharmaceutical Systems and Diabetes Care units," stated Edward J. Ludwig, Chairman and Chief Executive Officer. "In the face of a challenging global economy, we exceeded our overall expectations in the quarter and, as a result, we are revising our revenue and earnings guidance to the high end of the range previously provided for this year. We remain confident that our focus on productivity improvements and disciplined expense management, along with our ongoing investments in long-term growth opportunities, will ensure BD's future success."

FULL YEAR 2009 Guidance Ending September ^a

	Full Year 2009 Guidance	Full Year 2008 Reported	Period Change
GAAP EPS	$4.95 to $5.00	$4.46	11% to 12%

Source: See Release, July 30, 2009

^a The above forecasts reflect the Company's current and preliminary views and are therefore subject to change. Please refer to the Company's Safe Harbor Statement (usually in press releases) for the factors that could cause actual results to differ materially from those contained in any forward-looking statement.

Comments & Business Outlook

Wed, 01 Jul 2009 04:00:00 GMT

'In the face of global economic pressures, we are pleased to have achieved top-line growth in all three segments after adjusting for the negative impact of foreign currency translation. This growth, along with our continued focus on disciplined expense and currency risk management, has enabled us to deliver adjusted earnings in line with our expectations,' stated Edward J. Ludwig, Chairman and Chief Executive Officer. 'Our strong performance for the first half of fiscal 2009, combined with our commitment to continue to drive efficiency throughout BD, gives us the confidence to reaffirm our guidance for full-year adjusted earnings.'

Source: PR Newswire (April 28, 2009)

Comments & Business Outlook

Thu, 29 Jan 2009 05:00:00 GMT

Guidance Report:

2009 Fiscal Full Year Guidance

2009 Guidance	2008 EPS	Implied EPS Growth Rate
$4.95	$4.46	9% to 11%

"BD is off to a solid start to fiscal 2009. In particular, we continue to see strength in our Biosciences and Diagnostics segments and strong sales of insulin delivery products," said Edward J. Ludwig, Chairman and Chief Executive Officer. "In addition, our strong earnings per share growth has given us the confidence to raise guidance for fiscal 2009."

Source: PR Newswire (January 28, 2009)